HedgeMountain

Antara Capital LP

New York, NY · CRD 298247
Hedge fund manager

Antara Capital LP is an SEC-registered investment adviser based in New York, NY that reports managing 2 hedge funds on Form ADV. It reports $537.4 million in regulatory assets under management. Its private funds, of all types, hold $537.4 million in gross assets. Its disclosed U.S. stock holdings returned an estimated -30.9% 2025 YTD through Mar 31 (S&P 500: -4.5%), based on 13F filings. Over a longer period they returned an estimated -10.6% from Q3 2024 to Q1 2025, compared with +2.8% for the S&P 500, based on 13F filings.

Regulatory assets under management
$537.4 millionForm ADV Item 5.F
Gross assets of private funds
$537.4 millionAll private fund types, Form ADV
Hedge funds managed
22 private funds in total
Employees
4Form ADV Item 5.A
Registration
SEC-registered adviserCRD 298247
Latest Form ADV
03/31/2026Disciplinary disclosures: none reported

Estimated 13F portfolio performance

Est. 2025 YTD-30.9%Through Q1 2025 · S&P 500 -4.5%
Est. 2-year return-10.6%Q3 2024 – Q1 2025
S&P 500+2.8%Same quarters, price only
13F holdings$490,1833 positions, 2025-09-30
$89$109$129Q3 2024Q4 2024Q1 202513F est. $89S&P 500 $103
QuarterEst. 13F returnS&P 500
Q1 2025-30.9%-4.5%
Q4 2024+34.7%+2.1%
Q3 2024-4.0%+5.4%

Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures

Largest disclosed holdings

  • Currenc Group Inc$442,176
  • Aspire Biopharma Hldgs Inc$41,797
  • Aspire Biopharma Hldgs Inc$6,210

As of 2025-09-30, from 13F filing by Antara Capital LP.

From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. HedgeMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures